RT Journal Article
SR Electronic
T1 Converging molecular evolution in acute myeloid leukaemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.03.20222885
DO 10.1101/2020.11.03.20222885
A1 Engen, Caroline
A1 Hellesøy, Monica
A1 Dowling, Tara Helén
A1 Eldfors, Samuli
A1 Ferrell, Brent
A1 Gullaksen, Stein-Erik
A1 Popa, Mihaela
A1 Brendehaug, Atle
A1 Karjalainen, Riikka
A1 Mejlænder-Andersen, Eline
A1 Majumder, Muntasir Mamun
A1 Porkka, Kimmo
A1 Hovland, Randi
A1 Bruserud, Øystein
A1 Irish, Jonathan
A1 Heckman, Caroline
A1 McCormack, Emmet
A1 Gjertsen, Bjørn T.
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.03.20222885.abstract
AB Acute myeloid leukaemia (AML) is a highly heterogeneous disease. Here, we decipher the disease composition of a single AML patient through longitudinal sampling scrutinized by high-resolution genetic and phenotypic approaches, including sequencing, immunophenotyping, ex vivo drug sensitivity testing and establishment of patient-derived xenograft models. Throughout the disease course we identified patterns of both divergent and convergent molecular evolution within the leukemic compartment. We identified at least six discrete leukaemia initiating cell populations, of which five were characterised by known recurrent mutations in AML. These populations partly correlated with immunophenotypically defined cell subsets, drug sensitivity profiles and population-specific potential for engraftment in immunodeficient mice. Our results indicate that the genetic and phenotypic development are closely intertwined, and that diversity in the leukaemic gene-environment likely influences disease trajectories.SIGNIFICANCE Novel therapeutic approaches in AML are characterised by targeting molecular mechanisms thought to drive leukemogenesis, but emergent evidence suggests that intra-leukemic composition may be more diverse than previously appreciated. Through in-depth genetic and phenotypic characterization of the disease course of a single AML patient, we demonstrate a high degree of inter-individual complexity that exceeds the prevailing disease conception. The temporal molecular landscape of this patient suggests that leukemogenic transitions may not be categorically monoclonal. Patterns of converging molecular evolution further imply that higher levels of biological organisation than the molecular machinery of single cells may influence leukemogenic trajectories. Disease dynamics, relational properties and causal contribution from several levels of biological organization comes into conflict with the linear monocausal explanatory model on which precision oncology is largely built. This may have implications for current precision oncology oriented prectices, including molecular categorization, molecular therapeutic targeting and predictive models.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants provided by The Research Council of Norway, Helse Vest health trust and the Norwegian Cancer Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been performed in accordance with the Declaration of Helsinki and in agreement with approved local protocols. The study was approved by the regional ethics committee; REK Vest, University of Bergen, Bergen, Norway (project REK2012/2245). Before study initiation, the subject provided written informed consent. All animal studies were approved by The Norwegian Animal Research Authority and were conducted according to the European Convention for the Protection of Vertebrates Used for Scientific Purposes, in an AAALAC accredited institution; The Laboratory Animal Facility at the University of Bergen.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in article supplementary material